Compare Medpace Holdings Inc (MEDP) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs OneSpan Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while OneSpan Inc trades at $18.22 (market cap $662.97M). The key difference: Medpace Holdings Inc is far larger — about 25.4× OneSpan Inc's market cap, and OneSpan Inc pays a 2.89% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and OneSpan Inc for 18 Days on average.
| MEDP | OSPN | |
|---|---|---|
Market Cap | $16.82B | $662.97M |
Volume | 223,093 | 616,882 |
Sector | Health | Technology |
52-Week High | $630.19 | $18.42 |
52-Week Low | $393.42 | $10.15 |
Typical Hold Time | 14 Days | 18 Days |
Enterprise Value | $16.44B | $632.05M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
OneSpan (OSPN) trades at $18.01, up 1.75% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 27.76% net margin and consistent earnings beats, though 2026 projections show slight margin compression. Recent product innovation with DigipassONE and institutional interest from Deutsche Bank highlight growth potential amid competitive pressures.
Outlook remains positive with 67% analyst buy ratings and attractive valuation at 10.16 P/E, but investors face risks from subscription transition execution and market volatility. The stock's current technical positioning near key resistance at $19 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
